Zynex Announces Investor Relations Initiative
20 Dicembre 2013 - 3:30PM
Marketwired
Zynex Announces Investor Relations Initiative
LONE TREE, CO--(Marketwired - Dec 20, 2013) - Zynex, Inc.
(OTCQB: ZYXI), a provider and developer of non-invasive medical
devices for electrotherapy, stroke rehabilitation, and neurological
diagnosis, announced today that it has enabled Level 2 quote
visibility for investors though the OTC Markets Group.
With this upgrade investors and traders in Zynex common stock
can now access real-time bid/ask prices, size and full quote depth
for free on the OTC Markets Group and Zynex corporate websites. The
company's Investor Relations website is available at
www.ir-site.com/zynex.
"We are excited to move ahead and enable Level 2 quote
availability," said Thomas Sandgaard, CEO and founder of Zynex Inc.
"Being traded on the OTCQB has helped raise awareness for the
company, and we believe access to Level 2 quotes provides a more
transparent market for our current investors, as well as helping us
to attract new investors as we execute on our turnaround
strategy."
About OTC Markets Group Inc. OTC Markets Group Inc. (OTCQX:
OTCM) operates Open, Transparent and Connected financial
marketplaces for 10,000 U.S. and global securities. Through our OTC
Link® ATS, we directly link a diverse network of broker-dealers
that provide liquidity and execution services for a wide spectrum
of securities. We organize these securities into marketplaces to
better inform investors of opportunities and risks - OTCQX®, The
Best Marketplace with Qualified Companies; OTCQB®, The Venture
Stage Marketplace with U.S. Reporting Companies; and OTC Pink®, The
Open Marketplace with Variable Reporting Companies. Our data-driven
platform enables investors to easily trade through the broker of
their choice at the best possible price and empowers a broad range
of companies to improve the quality and availability of information
for their investors. To learn more about how we create better
informed and more efficient financial marketplaces, visit
www.otcmarkets.com.
OTC Link® ATS is operated by OTC Link LLC, member FINRA/SIPC and
SEC regulated ATS.
About Zynex Zynex (founded in 1996), operates under five primary
business segments; Zynex Medical, Zynex NeuroDiagnostics, Zynex
Monitoring Solutions, Zynex International and Zynex Billing and
Consulting. Zynex Medical engineers, manufactures, markets and
sells its own design of electrotherapy medical devices for
electrotherapy, used for pain management and rehabilitation. Zynex
Medical's product lines are fully developed, FDA-cleared and
commercially sold world-wide. Zynex NeuroDiagnostics, sells the
company's proprietary NeuroMove device designed to help stroke and
spinal cord injury patients and is currently expanding into markets
for EMG, EEG, sleep pattern, auditory and nerve conductivity
neurological diagnosis devices through product development and
acquisitions. Zynex Monitoring Solutions, currently in the
development stage, was established to develop and market medical
devices for non-invasive cardiac monitoring. Zynex
International is dedicated to supporting sales and marketing of
Zynex products worldwide through a network of medical distributors.
Zynex Billing and Consulting division provides medical billing and
consulting service for offices and hospitals. For additional
information, please visit: www.ir-site.com/zynex.
Safe Harbor Statement Certain statements in this release are
"forward-looking" and as such are subject to numerous risks and
uncertainties. Actual results may vary significantly from the
results expressed or implied in such statements. Factors that could
cause actual results to materially differ from forward-looking
statements include, but are not limited to, the need to obtain
additional capital in order to grow our business, our ability to
engage additional sales representatives, the success of such
additional sales representatives, the need to obtain FDA clearance
and CE marking of new products, the acceptance of new products as
well as existing products by doctors and hospitals, larger
competitors with greater financial resources, the need to keep pace
with technological changes, our dependence on the reimbursement
from insurance companies for products sold or rented to our
customers, acceptance of our products by health insurance
providers, our dependence on third party manufacturers to produce
our goods on time and to our specifications, implementation of our
sales strategy including a strong direct sales force, the uncertain
outcome of pending material litigation and other risks described in
our filings with the Securities and Exchange Commission including
the "Risk Factors" section of our Annual Report on Form 10-K for
the year ended December 31, 2012.
Contact: Zynex, Inc. Investor Relations 303-703-4906
Grafico Azioni OTC Markets (QX) (USOTC:OTCM)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni OTC Markets (QX) (USOTC:OTCM)
Storico
Da Mar 2024 a Mar 2025
